Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short Course Quinine Plus SP for P. Falciparum Malaria
NCT00167739Phase 4Completed
- Sponsor
- Albert Schweitzer Hospital
- Start
- Apr 2003
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of quinine and sulfadoxine + pyrimethamine in malaria, sponsored by Albert Schweitzer Hospital. Primary endpoint: Proportion of cured patients at 28 days. Started Apr 2003; status: completed.
02
Drugs
quininesulfadoxine + pyrimethamine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT00167739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00167739.